Allogene Therapeutics, Inc. focuses on developing allogeneic CAR T-cell therapies for cancer treatment, aiming to provide off-the-shelf immunotherapies.
Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.461.0M$, 2026▼38.2% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.0.0$, 2024